S&P 500

5.303,27

0,12%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Ocugen Inc (OCGN)
Ocugen Inc (OCGN) Notícias

OCGN

Ocugen (OCGN)

Ocugen Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:OCGN

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
17/05/2024	17:30	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:OCGN	Ocugen Inc
15/05/2024	07:30	GlobeNewswire Inc.	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy	NASDAQ:OCGN	Ocugen Inc
14/05/2024	16:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCGN	Ocugen Inc
14/05/2024	09:00	GlobeNewswire Inc.	Ocugen Provides Business Update with First Quarter 2024 Financial Results	NASDAQ:OCGN	Ocugen Inc
14/05/2024	08:18	IH Market News	US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report	NASDAQ:OCGN	Ocugen Inc
14/05/2024	07:32	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:OCGN	Ocugen Inc
10/05/2024	17:15	Edgar (US Regulatory)	Form 8-A12G - Registration of securities [Section 12(g)]	NASDAQ:OCGN	Ocugen Inc
10/05/2024	17:05	GlobeNewswire Inc.	Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock	NASDAQ:OCGN	Ocugen Inc
10/05/2024	08:45	GlobeNewswire Inc.	Ocugen to Present at May 2024 Investor Conferences	NASDAQ:OCGN	Ocugen Inc
03/05/2024	08:30	GlobeNewswire Inc.	Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results	NASDAQ:OCGN	Ocugen Inc
02/05/2024	08:15	GlobeNewswire Inc.	Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress	NASDAQ:OCGN	Ocugen Inc
29/04/2024	07:45	GlobeNewswire Inc.	Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024	NASDAQ:OCGN	Ocugen Inc
26/04/2024	10:05	GlobeNewswire Inc.	UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting	NASDAQ:OCGN	Ocugen Inc
26/04/2024	07:30	GlobeNewswire Inc.	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting	NASDAQ:OCGN	Ocugen Inc
19/04/2024	08:13	GlobeNewswire Inc.	Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy	NASDAQ:OCGN	Ocugen Inc
12/04/2024	08:30	GlobeNewswire Inc.	Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets	NASDAQ:OCGN	Ocugen Inc
10/04/2024	08:02	GlobeNewswire Inc.	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	NASDAQ:OCGN	Ocugen Inc
08/04/2024	07:30	GlobeNewswire Inc.	Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication	NASDAQ:OCGN	Ocugen Inc
05/04/2024	08:02	GlobeNewswire Inc.	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy	NASDAQ:OCGN	Ocugen Inc
02/04/2024	09:00	GlobeNewswire Inc.	Ocugen Provides Business Update with Certain Financials for the Year Ending 2023	NASDAQ:OCGN	Ocugen Inc
01/04/2024	19:08	GlobeNewswire Inc.	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease	NASDAQ:OCGN	Ocugen Inc
01/04/2024	18:43	GlobeNewswire Inc.	Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023	NASDAQ:OCGN	Ocugen Inc
18/03/2024	07:30	GlobeNewswire Inc.	Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer	NASDAQ:OCGN	Ocugen Inc
13/03/2024	09:00	GlobeNewswire Inc.	Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410	NASDAQ:OCGN	Ocugen Inc
06/03/2024	09:30	GlobeNewswire Inc.	Ocugen to Present at Investing in Cures Summit	NASDAQ:OCGN	Ocugen Inc
28/02/2024	10:00	GlobeNewswire Inc.	Ocugen Clinical Showcase Webcast Now Available	NASDAQ:OCGN	Ocugen Inc
26/02/2024	10:30	GlobeNewswire Inc.	Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit	NASDAQ:OCGN	Ocugen Inc
22/02/2024	18:05	GlobeNewswire Inc.	Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST	NASDAQ:OCGN	Ocugen Inc
21/02/2024	18:05	GlobeNewswire Inc.	Ocugen to Present at 2024 BIO CEO & Investor Conference	NASDAQ:OCGN	Ocugen Inc
14/02/2024	09:30	GlobeNewswire Inc.	Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024	NASDAQ:OCGN	Ocugen Inc